alvimopan
Trade name: entereg
Approved
May 20, 2008
Alvimopan (LY246736, ADL 8-2698, trade name Entereg) is a potent, peripherally selective mu-opioid receptor antagonist. Alvimopan was developed by Adolor Corporation (now Cubist Pharmaceuticals) and GlaxoSmithKline for the treatment of postoperative ileus. Postoperative ileus is the impairment of gastrointestinal motility after intra-abdominal surgery or other non-abdominal surgeries. This may potentially delay gastrointestinal recovery and hospital discharge until its resolution. Morphine and other mu-opioid receptor agonists are universally used for the treatment of acute postsurgical pain; however, they are known to have an inhibitory effect on gastrointestinal motility and may prolong the duration of postoperative ileus. Following oral administration, alvimopan antagonizes the peripheral effects of opioids on gastrointestinal motility and secretion by competitively binding to gastrointestinal tract mu-opioid receptors. — NCATS
Clinical trial activity
24 trials · 16 clinical orgs · 8 marketing orgs
Earliest trial started Mar 1, 2001 (NCT00388258)
Timeline
2000s
- Jan 1, 2001
- Jan 1, 2003
- May 20, 2008
Adolor Corp — Earliest FDA Approval
- May 20, 2008
Adolor Corp — NDA Organization
- May 20, 2008
Cubist — NDA Secondary Org
2010s
- Dec 19, 2019
Teva — Marketing Organization
2020s
- Jan 24, 2023
Endo Pharmaceuticals — Marketing Organization
- Jan 24, 2023
Par Pharmaceuticals — Marketing Organization
- Jan 24, 2023
Bristol-Myers Squibb — Marketing Organization
- Jan 24, 2023
PH HEALTH — Marketing Organization
- Aug 31, 2023
Hikma — Marketing Organization
Indications
Approved for
Studied for
- Acute Pain · Phase 4
- Colorectal Surgery · Phase 4
- Constipation · Phase 4
- Fallopian Tube Neoplasms · Phase 3
- General Surgery · Phase 4
- Hamartoma · Phase 3
- Ileus · Phase 4
- Intestinal Diseases · Phase 3
- Intestinal Neoplasms · Phase 4
- Laparoscopy · Phase 2
- Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 3
- Postoperative Complications · Phase 4
- Postoperative Pain · Phase 4
- Urinary Bladder Neoplasms · Phase 3
Mechanism of action
- Mu opioid receptorANTAGONIST
OPRM antagonist
Approval history
- approvedMay 20, 2008
Chemistry & pharmacology
SMILES
C[C@H]1CN(C[C@H](CC2=CC=CC=C2)C(=O)NCC(O)=O)CC[C@@]1(C)C3=CC=CC(O)=C3- Mol. weight
- 424.5326 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaAlvimopan ↗
- NCATSQ153V49P3Z ↗
- ChEMBLCHEMBL270190 ↗
Also known as
- adl 8-2698
- adl 8-2698
- adl 8-2698
- adl8-2698
- alvimopan
- alvimopan
- alvimopan
- alvimopan
- alvimopan
- alvimopan
- alvimopan
- alvimopan
- alvimopan
- alvimopan
- alvimopan anhydrous
- alvimopan anhydrous
- alvimopan anhydrous
- alvimopan anhydrous
- alvimopan dihydrate
- alvimopan dihydrate
- alvimopan dihydrate
- alvimopan dihydrate
- alvimopan dihydrate
- anhydrous alvimopan
- anhydrous alvimopan
- anhydrous alvimopan
- entereg
- entereg
- entereg
- entereg
- entereg
- ly246736
- ly246736
- ly 246736
- ly-246736
- ly-246736
- trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06703476 | Phase 3 | Nov 21, 2024 | Memorial Sloan-Kettering Cancer Center |
| NCT04405037 | Phase 4 | Jul 1, 2020 | The Cleveland Clinic |
| NCT03352414 | Phase 2 | Mar 8, 2018 | University of California, San Diego |
| NCT03216525 | Phase 3 | Jul 31, 2017 | Harvard University |
| NCT03068975 | Phase 4 | Apr 1, 2017 | Merck, University of Puerto Rico |
| NCT02785003 | Phase 4 | Jul 1, 2016 | Medical College of Wisconsin |
| NCT02789111 | Phase 4 | Jun 1, 2016 | Merck, University of Virginia |
| NCT02742181 | Phase 3 | May 1, 2016 | Case Western Reserve University, Merck, University Hospitals Cleveland Medical Center |
| NCT02379858 | N/A | Jul 1, 2015 | Medical College of Wisconsin, Merck |
| NCT02218190 | N/A | Aug 1, 2014 | Washington University in St. Louis |
| NCT01704651 | Phase 3 | Jan 1, 2013 | Cubist, Mayo Clinic |
| NCT01258569 | Phase 2 | Nov 1, 2010 | Cubist, University of Connecticut |
| NCT01143259 | N/A | May 1, 2010 | Allegiance Health, Cubist |
| NCT00708201 | Phase 4 | Mar 1, 2009 | Cubist |
| NCT00331045 | Phase 2 | Apr 1, 2006 | Cubist, GlaxoSmithKline |
| NCT00241722 | Phase 3 | Aug 1, 2005 | Cubist, GlaxoSmithKline |
| NCT00256932 | Phase 3 | Aug 1, 2005 | Cubist, GlaxoSmithKline |
| NCT00259922 | Phase 3 | Aug 1, 2005 | Cubist, GlaxoSmithKline |
| NCT00135577 | Phase 2 | Sep 1, 2004 | Cubist, GlaxoSmithKline |
| NCT00205842 | Phase 3 | Jun 1, 2004 | Cubist, GlaxoSmithKline |
Organizations
Research & Development (16)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cubist | For profit | 14 | 11 | 4 | 2001 |
| GlaxoSmithKline | For profit | 10 | 0 | 2 | 2001 |
| Merck | For profit | 4 | 0 | 3 | 2015 |
| Medical College of Wisconsin | Academic/Hospital | 2 | 2 | 2 | 2015 |
| Allegiance Health | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Case Western Reserve University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2024 |
| The Cleveland Clinic | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University Hospitals Cleveland Medical Center | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of California, San Diego | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Connecticut | Academic/Hospital | 1 | 1 | 1 | 2010 |
| University of Puerto Rico | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of Virginia | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2014 |
Marketing (8)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Adolor Corp | For profit | NDA | May 20, 2008 |
| Bristol-Myers Squibb | For profit | MKTG | Jan 24, 2023 |
| Cubist | For profit | NDA2 | May 20, 2008 |
| Endo Pharmaceuticals | For profit | MKTG | Jan 24, 2023 |
| Hikma | For profit | MKTG | Aug 31, 2023 |
| PH HEALTH | For profit | MKTG | Jan 24, 2023 |
| Par Pharmaceuticals | For profit | MKTG | Jan 24, 2023 |
| Teva | For profit | MKTG | Dec 19, 2019 |